Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 14/20 | 0.52 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279820 | 0.92 | NTRK1 (0.59) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL4278072 | 0.92 | NTRK1 (0.59) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL4293054 | 0.89 | IGF1R (0.63) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL4285353 | 0.85 | NTRK1 (0.57) | CDK2CCNA2CCNA1NTRK1IGF1R | |
| SCHEMBL4287193 | 0.84 | NTRK1 (0.64) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL4279135 | 0.83 | NTRK1 (0.63) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL4285322 | 0.83 | IGF1R (0.64) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL4278208 | 0.81 | NTRK1 (0.70) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL4279848 | 0.81 | IGF1R (0.73) | CDK2CCNA2CCNA1NTRK1NTRK3 | |
| SCHEMBL4282966 | 0.81 | NTRK1 (0.65) | CDK2CCNA2CCNA1NTRK1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | claimed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | claimed |
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | MAP3K19, CDK2, MAP3K1 | CDK2 2/4885CCNA2 283/4885CCNA1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.